Anemia in heart failure-A concise review

Vasu, Sujethra; Kelly, Davidt .; Lawson, William

doi:10.1002/clc.4960281003

Cited by 10 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…У цьому контексті використання інгібіторів ангіотензин перетворюючого ферменту (ІАПФ) та блокаторів рецептора ангіотензину можуть перешкоджати синтезу еритропоетину та чутливості до нього кісткового мозку. Ще один механізм -при використанні ІАПФ підвищуються рівні N-ацетил-церил-аспартиллізин-проліну, який є інгібітором еритропоезу [32]. Наприклад, лікування еналаприлом було пов'язане з підвищенням ризику розвитку анемії на 56% через 1 рік після лікування [2].…”

Section: патогенез анемії та дефіциту заліза у пацієнтів із хронічною...unclassified

Prevalence and Pathogenesis of Anemia in Chronic Heart Failure

Ханюков¹,

Kuchuk²,

Sapozhnychenko³

2022

Ukr. ž. med. bìol. sportu

View full text Add to dashboard Cite

Anemia is often associated disease in patients with chronic heart failure, which reduces exercise tolerance, quality of life and worsens the prognosis in the patients. The recommendations of the leading associations of cardiology include the correction of iron deficiency and anemia in the context of the treatment of patients with chronic heart failure. Such influence and modern recommendations determine the relevance of knowledge of the prevalence and pathogenesis of anemia and iron-deficiency conditions in chronic heart failure. The purpose of the study was to review the literature illustrating current data about prevalence and pathogenesis of anemia and iron deficiency in patients with chronic heart failure. Materials and methods. This work presents review of literature about prevalence and pathogenesis of anemia and iron deficiency in patients with chronic heart failure, based on a search of English-language articles in the PubMed database for the last 20 years, by keywords – anemia, iron deficiency, chronic heart failure, pathogenesis, prevalence. Results and discussion. The frequency of anemia that patients with chronic heart failure ranges have are from 4% to 30-70% of cases, according to several studies. Such a variety of data is associated with different degrees of severity of heart failure in different studies, but they unanimously confirm the information about the significant prevalence of this condition in the studied population cohort. Iron deficiency is an important comorbid condition that patients with heart failure have and is observed in an average of 30-50% of cases, according to some data, the frequency reaches a maximum of 70-83%. Iron deficiency is the most common cause of anemia, but it is particularly interesting that approximately 46% of patients with iron deficiency do not have anemia. The following 6 factors that can be the cause of anemia individually or in combination that patients with chronic heart failure have, have been identified: iron deficiency, inflammation, erythropoietin level, medications, hemodilution, medullary dysfunction. The causes of absolute iron deficiency are anorexia, cachexia, malabsorption of iron due to intestinal edema and hepcidin-induced suppression of iron transporters, such as ferroportin, functional – chronic inflammatory state, which leads to an increase in the level of pro-inflammatory cytokines, such as interleukin-1, interleukin-6, interleukin-18, tumor necrosis factor-, which, in turn, induces the synthesis of hepcidin and, accordingly, decreases the expression of ferroportin with a decrease in the transition of iron into the state of circulation and stimulation of sequestration in macrophages of the reticuloendothelial system. Conclusion. Better understanding of the pathogenesis of these conditions that patients with chronic heart failure have, will allow the development of new methods of treatment

show abstract

Section: патогенез анемії та дефіциту заліза у пацієнтів із хронічною...unclassified

Prevalence and Pathogenesis of Anemia in Chronic Heart Failure

Ханюков¹,

Kuchuk²,

Sapozhnychenko³

2022

Ukr. ž. med. bìol. sportu

View full text Add to dashboard Cite

show abstract

“…For example, treatment with enalapril was associated to an intent-to-treat model, with a rise in the risk of developing new anemia at 1 year by 56% ( 17 ). The levels of N acetyl-seryl-aspartyl-lysin-prolyn, an erythropoiesis inhibitor, rise with ACEI usage, causing a fall in erythropoiesis and anemia ( 18 ).…”

Section: Introductionmentioning

confidence: 99%

Anemia in heart failure - from guidelines to controversies and challenges

Sîrbu

Floria

Dascalita³

et al. 2018

Anatol J Cardiol

View full text Add to dashboard Cite

Anemia associated with heart failure is a frequent condition, which may lead to heart function deterioration by the activation of neuro-hormonal mechanisms. Therefore, a vicious circle is present in the relationship of heart failure and anemia. The consequence is reflected upon the patients’ survival, quality of life, and hospital readmissions. Anemia and iron deficiency should be correctly diagnosed and treated in patients with heart failure. The etiology is multifactorial but certainly not fully understood. There is data suggesting that the following factors can cause anemia alone or in combination: iron deficiency, inflammation, erythropoietin levels, prescribed medication, hemodilution, and medullar dysfunction. There is data suggesting the association among iron deficiency, inflammation, erythropoietin levels, prescribed medication, hemodilution, and medullar dysfunction. The main pathophysiologic mechanisms, with the strongest evidence-based medicine data, are iron deficiency and inflammation. In clinical practice, the etiology of anemia needs thorough evaluation for determining the best possible therapeutic course. In this context, we must correctly treat the patients’ diseases; according with the current guidelines we have now only one intravenous iron drug. This paper is focused on data about anemia in heart failure, from prevalence to optimal treatment, controversies, and challenges.

show abstract

“…[ 18 ] The levels of an erythropoiesis inhibitor, N-acetylseryl-aspartyl-lysin-prolyn, rise with the usage of ACE inhibitor, causing inhibition of erythropoiesis and manifestation of anemia. [ 19 ] A subanalysis of the PAERI study comparing 3,361 patients with diabetic kidney disease with 1,861 patients with non-diabetic CKD found that the diabetic patients were treated more often with ACE inhibitors (73.9 vs. 55.4%, P < 0.0001) and had a higher prevalence of anemia (52.7 vs. 39.4%, P < 0.0001). [ 20 ]…”

Section: Angiotensin-converting Enzyme Inhibitors and Its Relation With Anemiamentioning

confidence: 99%

Anaemia in Heart Failure Patients, Associated with Angiotensin – Renin – Aldosterone System Altering Medications

2021

View full text Add to dashboard Cite

Heart failure (HF) remains one of the most common diseases and one of the major causes of death worldwide. HF is often associated with other chronic diseases, most commonly with anemia. Anemia increases patients' mortality and lowers their quality of life. There are a few pathophysiological mechanisms that explain anemia in patients with HF – hemodilution, absolute or functional iron deficiency, activation of the inflammatory cascade, chronic kidney disease, and impaired erythropoietin production and activity. Moreover, congestive HF is often treated with angiotensin-converting enzyme inhibitors and aldosterone receptors blockers, which could be linked to the development of anemia.

show abstract

Anemia in heart failure-A concise review

Cited by 10 publications

References 31 publications

Prevalence and Pathogenesis of Anemia in Chronic Heart Failure

Prevalence and Pathogenesis of Anemia in Chronic Heart Failure

Anemia in heart failure - from guidelines to controversies and challenges

Anaemia in Heart Failure Patients, Associated with Angiotensin – Renin – Aldosterone System Altering Medications

Contact Info

Product

Resources

About